Janux Therapeutics
Agent50Agent Readiness: 50/100. Top 25%. Measured by StartupHub.ai. Median 41.Trust85Data Trust: 85/100. Top 25%. Measured by StartupHub.ai. Median 61.A clinical-stage biopharmaceutical company developing novel immunotherapies.
About
Janux Therapeutics is a clinical-stage biopharmaceutical company developing precision-engineered immunotherapies. Their proprietary TRACTr, TRACIr, and ARM platforms are designed to selectively modulate T cells to fight cancer and autoimmune diseases, aiming to transform patients' lives. They are currently evaluating their lead tumor-activated T cell engager (TRACTr) in a clinical trial for prostate cancer.
Listed competitors
Develops, manufactures, and markets radiopharmaceuticals for diagnostic and therapeutic applications.
Biopharmaceutical company developing antibody-based therapeutics for cancer and autoimmune diseases.
Biotechnology company developing and commercializing cell therapies for cancer treatment.
Global biopharmaceutical company focused on oncology and neuroscience treatments.
A global biotechnology company discovering, developing, manufacturing, and delivering innovative human therapeutics.
A biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases.
Biopharmaceutical company developing T-cell therapies for solid tumor cancers.
Also in this space
Clinical-stage biopharmaceutical company developing microbiome-derived immunotherapies for cancer and immune diseases.
Shares Biotechnology, Drug Discovery
Biomica is developing a novel microbiome-based platform for the treatment of cancer.
Shares Biotech, Drug Discovery
Moderna is a biotechnology company pioneering mRNA medicine, best known for its COVID-19 vaccine and a broad pipeline of mRNA-based therapeutics.
Shares Biotechnology, Pharmaceuticals
Global biopharmaceutical company pioneering mRNA-based immunotherapies and vaccines for cancer and infectious diseases.
Shares Biotechnology, Drug Discovery
Epicrispr Biotechnologies is a biotechnology company developing novel epigenetic therapies, with a lead program targeting Facioscapulohumeral Muscular Dystrophy (FSHD).
Shares Biotechnology, Biotech
Key facts
- Website
- januxrx.com
- Headquarters
- San Diego, California, USA
- Founded
- 2017
- Employees
- 110
- Total funding
- $181M (Series B)
- Business model
- B2B
Funding rounds
| Date | Round | Amount | Lead investors |
|---|---|---|---|
| 20 Apr 2021 | Series B | $125M | |
| 3 Mar 2021 | Series A | $56M | Avalon Ventures |
Tech stack
Detected on januxrx.com, last scanned 31 Oct 2026. Run your own scan
- Frontend
- jQuery
- Analytics
- Google Tag Manager
- SEO
- Yoast SEO
- CMS / Builders
- WordPress
- CDN
- Cloudflare
- Cookie consent
- OneTrust
Janux Therapeutics scores 39. Does yours?
That is its Ahrefs DR: the backlink strength of a domain, on the Ahrefs 0 to 100 scale. Paste your website and you get yours in about a minute.
Frequently asked
Is Janux Therapeutics trustworthy and reputable?
StartupHub's Data Trust & Reputation score for Janux Therapeutics is 85 out of 100, a trusted rating, based on site security posture, privacy practices, malware and phishing checks, and public reputation signals.
How much funding has Janux Therapeutics raised?
Janux Therapeutics has raised a total of $181M in funding. The most recent round on record is Series B.
How many employees does Janux Therapeutics have?
Janux Therapeutics has approximately 110 people on record.
Public record
SEC filings, insider activity, nonprofit links and pay benchmarks for Janux Therapeutics
